Clinical trials: Covid19 Vaccine
COVID-19 Pneumonia
COVID19 Oral Vaccine Consisting of Bacillus Subtilis Spores
This is a study trial to assess the effectiveness of the immune response stimulated by the genetically engineered Bacillus subtilis which express and display Spike protein of the SARS-COV2 on the spore coat.
- Trial name
- NCT05239923
- Testing
- Bacillus subtilis
- Where
- 2 sites in Hong Kong, Iran
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- DreamTec Research Limited
COVID-19 Vaccine
Safety and Immunogenicity of the Inactivated Koçak-19 Inaktif Adjuvanlı COVID-19 Vaccine Compared to Placebo
The objective of this study is to determine the safety and immunogenicity of two different strengths (4 µg and 6 µg) of an inactivated COVID-19 Vaccine compared to placebo so that to demonstrate the safety and efficacy in…
- Trial name
- NCT04838080
- Testing
- Koçak-19 Inaktif Adjuvanlı COVID-19 Vaccine 4 µg/0.5 ml Vaccine, Koçak-19 Inaktif Adjuvanlı COVID-19 Vaccine 6 µg/0.5 ml Vaccine
- Where
- Turkey (Türkiye)
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Kocak Farma
Covid-19
Association of the Risk for Thrombotic Thrombocytopenia Syndrome and Exposure To COVID-19 Vaccines
Background/Rationale: A very rare syndrome of thrombosis associated with low platelets has been reported in a few cases of recent exposure to COVID-19 vaccine.
- Trial name
- ATTEST (NCT05252442)
- Testing
- Pre-COVID-19, COVID-19, COVID-19 vaccination roll-out
- Where
- United Kingdom
- Volunteers
- 7,641,136 people
- Sponsor
- AstraZeneca
COVID-19 Disease
Efficacy, Immunogenicity and Safety of BBIBP-CorV Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.
To expand the access and delivery of COVID-19 Vaccines in Africa (ECOVA), the investigators will conduct a phase 3, individually randomized, observer-blind, controlled (influenza vaccine) trial to evaluate the safety and efficacy…
- Trial name
- ECOVA-01 (NCT04984408)
- Testing
- BBIBP-CorV - Inactivated SARS-CoV-2 vaccine (Vero cell), influenza season quadrivalent Influenza Vaccine (Flu Quadrivalent)
- Volunteers
- 8,825 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
COVID-19, SARS-CoV-2 Infection
A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses
The goal of this clinical trial is to test two investigational COVID-19 booster vaccines, called CoTend-s3BXBB and CoTend-BXBB, in healthy volunteers ages 40-64.
- Trial name
- CONTENDER (NCT06810934)
- Testing
- CoTend-BXBB (SARS2-30404), CoTend-s3BXBB (SARS2-17032)
- Where
- 2 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Kara Chew
SARS CoV 2 Infection, COVID-19
PROSPECTIVE OPEN LABEL CLINICAL TRIAL TO ADMINISTER A BOOSTER DOSE OF PFIZER/BIONTECH OR MODERNA COVID-19 VACCINE IN HIGH-RISK INDIVIDUALS
The recent rise in infections with the Omicron variant of the SARS-CoV-2 is alarming. Equally disconcerting is the fact that individuals who were previously vaccinated (< 6 months) and have co-morbidities that are considered high…
- Trial name
- NCT05279365
- Testing
- Pfizer/BioNTech (BNT162b2), Moderna
- Where
- 4 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- DHR Health Institute for Research and Development
Adult Who Received a First Dose of an mRNA Vaccine (Pfizer-BioNTech or Moderna) and Need to Receive a Second Dose
Compare Immunological Efficacy of a Vaccine Regimen Combining Two Covid19 mRNA Vaccines (Pfizer-BioNTech and Moderna) With That of a Homologous Vaccination of Each Covid19 mRNA Vaccine
As part of the COVID 19 vaccine campaign, the two mRNA vaccines, BNT162b2 (COMIRNATY®) and mRNA-1273 COVID-19 vaccine Moderna, are administered in two doses in subjects without a history of SARS-CoV-2 infection .
- Trial name
- ARNCOMBI (NCT04900467)
- Testing
- Pfizer, Moderna
- Where
- France
- Volunteers
- 418 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Covid19, Vaccines
Text-based Interventions to Promote COVID-19 Vaccinations
This study investigates whether and which type of text-based interventions affect the take-up of the COVID-19 vaccine.
- Trial name
- NCT04800965
- Testing
- Patient MyChart Scheduling Link, Patient Educational Video, Enhanced Follow through Message
- Where
- United States
- Volunteers
- 200,000 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Vaccine Preventable Disease
COVID-19 Vaccine For Indirect Protection
The primary objective of this study is to test whether vaccinating adults ≥18 years in Hutterite colonies with mRNA-1273 (Moderna COVID-19) vaccine as compared to control (usual care) can prevent RT-PCR confirmed COVID-19 in…
- Trial name
- NCT04818736
- Testing
- COVID-19 Vaccination, Usual care
- Where
- Canada
- Volunteers
- healthy volunteers welcome
- Sponsor
- McMaster University
Covid19, SARS-CoV2 Infection
Monitoring the Effectiveness and Safety of COVID-19 Vaccines at National University of Colombia
There are relevant questions that need to be answered about the effectiveness and safety of COVID-19 vaccines. The objective of this observational study is to follow up the clinical outcomes after vaccination in all the…
- Trial name
- NCT04887246
- Testing
- COVID-19 vaccines
- Where
- Colombia
- Volunteers
- 4,078 people, healthy volunteers welcome
- Sponsor
- Universidad Nacional de Colombia
Coronavirus, SARS-CoV-2 Infection
A Phase-I Study of a Nanoparticle-based Peptide Vaccine Against SARS-CoV-2
This trial is Stage 2 of a 2-part adaptive trial. The study aims to investigate the safety of 2 doses of a T-cell priming specific cocktail of Coronaviruses peptides mounted on a gold nanoparticle.
- Conditions
- Coronavirus, SARS-CoV-2 Infection, COVID-19
- Trial name
- NCT05113862
- Testing
- LD Vehicle-GNP, LD PepGNP-Covid19, HD Vehicle-GNP
- Where
- Switzerland
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Gylden Pharma Ltd
COVID-19, Vaccines
Immunogenicity Evaluation of Omicron Variant-based Vaccine and a Trivalent Vaccine in Adults Against COVID-19 in Chile
Phase 2 clinical trial in adults previously vaccinated against SARS-CoV-2 in Chile with an initial schedule of two doses of CoronaVac® plus two booster doses with different vaccines.
- Trial name
- CoronaVarCL (NCT05593042)
- Testing
- CoronaVac®, Omicron Vaccine, Trivalent Vaccine
- Where
- 3 sites in Chile
- Volunteers
- 551 people, healthy volunteers welcome
- Sponsor
- Pontificia Universidad Catolica de Chile
Virus Diseases
A Study of the Safety of and Immune Response to Varying Doses of a Vaccine Against COVID-19 in Healthy Adults
The purpose of this study is to assess the safety, reactogenicity and immune response of a self-amplifying mRNA (SAM) lipid nanoparticle (LNP) platform with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike…
- Trial name
- NCT04758962
- Testing
- 1 µg CoV2 SAM (LNP)
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19, Vaccine Reaction
Evaluation of the Immunogenicity and Safety of Ad26.COV2.S's COVID-19 Vaccine
Phase II, non-randomized, open-label, comparative, national, multicenter trial in Mali, aimed to assess the humoral vaccine immune response induced by Ad26.COV2.S vaccine in 200 adults one month after receiving the complete…
- Conditions
- COVID-19, Vaccine Reaction, SARS CoV 2 Infection, Vaccine Adverse Reaction
- Trial name
- CoviComMali (NCT05409261)
- Testing
- Ad26.COV2.S
- Where
- Mali
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Healthy Volunteer
Emotional, Social, Cognitive and Behavioral Sequalae of the COVID-19 Pandemic
Background: COVID-19 has caused a high rate of deaths. The steps taken to control its spread have caused social isolation, changes in lifestyle, economic turmoil, and increased work-related stress.
- Trial name
- NCT04823988
- Where
- United States
- Volunteers
- 2,086 people
- Sponsor
- National Institute of Mental Health (NIMH)
Covid19
Safety and Immunogenicity of the Candidate Vaccine MVA-SARS-2-S and a Booster Vaccination With a Licensed Vaccine Against COVID-19
In this phase I first-in-human clinical trial, healthy volunteers in two different dose cohorts will be vaccinated twice with the candidate vaccine MVA-SARS-2-S.
- Trial name
- NCT04569383
- Testing
- MVA-SARS-2-S vaccinations (days 0 & 28), Comirnaty
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
COVID-19
Phase I Clinical Trial With New SARS-CoV-2 CoVacHGMix Type 5 Adenoviral Vector Vaccine
The CoVacHGMix adenoviral vector vaccine is a new vaccine developed to protect against SARS-CoV-2 and is a Phase I study designed based on adaptive clinical trial standards.
- Trial name
- NCT05526183
- Testing
- Adeno-viral vector vaccine
- Where
- Turkey (Türkiye)
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Ankara City Hospital Bilkent
COVID-19, Vaccine
Evaluation of Menstrual Irregularities and Abnormal Uterine Bleeding After Covid-19 Vaccine
Covid-19 vaccines offered a good opportunity to counteract the spread of Sars-Cov-2 infection among the general population, reducing significantly both morbidity and mortality.
- Conditions
- COVID-19, Vaccine, Menstrual Irregularity, Menopausal Bleeding
- Trial name
- MECOVAC-1 (NCT05083065)
- Testing
- Covid-19 vaccine
- Where
- Italy
- Volunteers
- 369 people, healthy volunteers welcome
- Sponsor
- Università degli Studi dell'Insubria
Covid19, Breakthrough Infection
Antibody After COVID-19 Vaccination
Chronic kidney disease (CKD) including patients on dialysis and kidney transplant recipients. represents the special subgroups of patients that required protection during the Severe Coronavirus Disease 2019 (COVID-19) pandemic…
- Conditions
- Covid19, Breakthrough Infection, CKD, Kidney Transplant
- Trial name
- NCT05057936
- Testing
- COVID vaccine
- Where
- Thailand
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Bangkok Metropolitan Administration Medical College and Vajira Hospital
COVID-19
SARS-CoV-2 Infection in COVID-19 Vaccinated Patients
Vaccination of the population is crucial in the fight against the COVID-19 pandemic. Although most available vaccines have an estimated efficacy against symptomatic infection of 65-95%, this can be significantly reduced if the…
- Trial name
- COVID-IVAC (NCT05060939)
- Testing
- COVID-19 vaccinated people
- Where
- France
- Volunteers
- 1,072 people
- Sponsor
- Hospices Civils de Lyon
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.